From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Emory Awarded Continuation Funds for NIH Tetramer Core Facility

by Global Biodefense Staff
March 26, 2013

NIH Tetramer LabThe National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) has awarded funding to Emory University for the continued operation of the NIH Tetramer Core Facility. 

In 1999, NIAID established the tetramer core facility at Emory as a two year subcontract to the NIAID AIDS Reagent Program (awarded to McKesson BioServices). The tetramer program continued through a separate contract to Emory University, which was set to expire this year. The new award to Emory is valued at $1,899,068.

The main goal of the NIH Tetramer Core Facility is to provide custom-made Major Histocompatibility Complex (MHC) tetramer reagents to the global research community.

MHC tetramers are valuable tools for the rapid and highly sensitive quantitation of antigen-specific T lymphocyte (T cell) from blood or tissue samples. Such assessments of T cell function can offer valuable insights into the magnitude of immune responses during the course of an infection or an immune-mediated disorder, or after vaccination or immune-based therapies. 

MHC tetramers are composed of four identical MHC molecules, each containing an antigen-specific peptide/ligand in the MHC ligand binding groove. The MHC molecules are labeled with biotin, allowing for tetramerization through the addition of a streptavidin-linked fluorophore. Tetramers are produced when the biotinylated MHC molecules attach to the four biotin-binding sites on streptavidin. 

NIAID has Memorandum of Understanding with Beckman Coulter, Inc., owner of commercialization rights for MHC class I tetramer technology. The agreement allows the NIH Tetramer Core Facility to provide specified Beckman Coulter MHC tetramers to the broader research community.

Since opening, the NIH Tetramer Core Facility has produced more than 4000 tetramer reagents, shipped to over 600 investigators in the US and abroad, including at least 15 countries. Investigators requesting reagents incur the cost of peptide production, shipping of the peptides to the NIH Tetramer Core Facility, and shipping of the tetramer reagents to their institution.

Further details are available under RFP-NIAID-DAIT-NIHAI2011132.

From Our Partners
Tags: AwardsNIH

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC